Markets Shrug Off Semi Weakness…And One Biopharma Stock Surges After Trial Results 6/24/24
CNBC's "Fast Money"
00:00
Biopharma Company's Stock Surges on Positive Drug Data
El Nylum's stock sees a surge following promising late-stage data on its drug for heart conditions, with the CEO discussing the drug's potential to become the new standard of care for ATTR cardiomyopathy. The chapter covers details on FDA application plans, regulatory approval expectations, and the company's timeline for bringing the medicine to market to achieve self-sustainable profitability by 2025.
Play episode from 30:45
Transcript
